StreetInsider.com News Articles

Form PRE 14A AEON Biopharma, Inc. For: Oct 13

Tue, 13 Oct 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20261013/27182018.html

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Fri, 09 Oct 2026 16:15:00 -0400

ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensation Committee of the Board of Directors on October 5, 2026 under the Company’s 2025 Employment Inducement Incentive Award Plan, which provides for the granting

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Fri, 09 Oct 2026 16:15:00 -0400

AEON Biopharma, Inc (AEON) PT Raised to $2 at Lake Street

Thu, 01 Oct 2026 08:52:00 -0400

Lake Street analyst Thomas Flaten raised the price target on AEON Biopharma, Inc (NYSE: AEON) to $2.00 (from $1.00) while maintaining a Buy rating.

AEON Biopharma gets FDA clarity on ABP-450 biosimilar pathway

Wed, 30 Sep 2026 08:00:48 -0400

AEON Biopharma, Inc. (NYSE American: AEON) announced it has received official minutes from a Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration regarding the development pathway for ABP-450, its proposed biosimilar to Botox (onabotulinumtoxinA).

The FDA indicated that comparative clinical studies previously conducted by Daewoong Pharmaceutical across several indications — including blepharospasm, upper limb spasticity, glabellar lines, and lateral canthal lines — may be submitted as supportive evidence, subject to scientific bridging to U.S.-licensed Botox and to ABP-450 as currently manufactured.

AEON proposed a two-stage comparative pharmacodynamic study using Compound Muscle Action Potential measurement in the

AEON Biopharma gets FDA feedback on ABP-450 biosimilar pathway

Wed, 30 Sep 2026 08:00:48 -0400

The FDA indicated that previously completed head-to-head comparative clinical studies conducted by Daewoong Pharmaceutical across several indications — including blepharospasm, upper limb spasticity, glabellar lines, and lateral canthal lines — may be submitted as supportive evidence, subject to scientific bridging to U.S.-licensed Botox and to ABP-450 as currently manufactured.

The FDA agreed in principle with AEON's proposed two-stage comparative pharmacodynamic study using

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

Wed, 30 Sep 2026 08:00:00 -0400

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work

AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026

AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path

ALISO VIEJO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

Wed, 30 Sep 2026 08:00:00 -0400

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work

AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026

AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path

Form 8-K AEON Biopharma, Inc. For: Sep 30

Wed, 30 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260930/27125580.html

AEON Biopharma reports pilot degradation data for ABP-450 vs. Botox

Wed, 09 Sep 2026 08:01:38 -0400

AEON Biopharma, Inc. (NYSE American: AEON) announced results from a pilot forced degradation study comparing its biosimilar candidate ABP-450 to Botox (onabotulinumtoxinA) under thermal and oxidative stress conditions, according to a press release dated Sept. 9, 2026.

Under thermal stress, both ABP-450 and Botox lost potency at comparable rates, with each molecule following a similar trajectory of rapid initial loss, reaching approximately half of initial observed potency by day 14. Under oxidative stress using two concentrations of hydrogen peroxide, methionine sites in both molecules oxidized to a comparable magnitude, measured by mass spectrometry peptide mapping.

The company described the results as an

AEON Biopharma reports pilot degradation data for ABP-450 vs. Botox

Wed, 09 Sep 2026 08:01:38 -0400

The company described the results as an

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

Wed, 09 Sep 2026 08:00:00 -0400

ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated

Results provide additional analytical evidence supporting comparability and establish the basis for AEON’s planned multi-lot comparability study

ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced positive results from a pilot forced degradation study comparing ABP-450 to BOTOX® under thermal and

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

Wed, 09 Sep 2026 08:00:00 -0400

ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated

Results provide additional analytical evidence supporting comparability and establish the basis for AEON’s planned multi-lot comparability study

Laidlaw Starts AEON Biopharma, Inc (AEON) at Buy

Wed, 09 Sep 2026 03:26:10 -0400

Laidlaw analyst Yale Jen initiates coverage on AEON Biopharma, Inc (NYSE: AEON) with a Buy rating and a price target of $1.80.

The analyst comments: “We are initiating coverage on AEON Biopharma with a Buy rating and 12-month $1.80 price target. AEON is a mid-development stage specialty pharma company focused on developing ABP-450 (prabotulinumtoxinA) as a potential full label in therapeutics Botox biosimilar. The initial analytical similarity results, which carries most of the evidentiary weight, are very promising in demonstrating ABP-450 is structurally identical to Botox. After the upcoming FDA BPD Type 2b meeting, we anticipate AEON to advance ABP 450

Laidlaw Starts AEON Biopharma, Inc (AEON) at Buy

Wed, 09 Sep 2026 03:26:10 -0400

Laidlaw analyst Yale Jen initiates coverage on AEON Biopharma, Inc (NYSE: AEON) with a Buy rating and a price target of $1.80.

AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference

Mon, 31 Aug 2026 08:00:00 -0400

ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026.

To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.

AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference

Mon, 31 Aug 2026 08:00:00 -0400

To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.

AEON Biopharma names ex-FDA neuroscience official as acting CRO

Mon, 24 Aug 2026 08:01:21 -0400

AEON Biopharma, Inc. (NYSE American: AEON) has designated Paul Lee, M.D., Ph.D., a former senior official at the U.S. Food and Drug Administration, as acting Chief Regulatory Officer, according to a company statement.

Dr. Lee will serve in the role through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, which has previously advised AEON on regulatory strategy for its lead candidate, ABP-450. He will lead regulatory strategy, oversee FDA interactions, and work with AEON's analytical, chemistry, manufacturing and controls, and clinical teams as the company advances ABP-450 under the 351(k) biosimilar pathway.

Dr. Lee spent more than seven years at

AEON Biopharma names ex-FDA neuroscience official as acting CRO

Mon, 24 Aug 2026 08:01:21 -0400

Dr. Lee spent more than seven years at

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer